OncLive TV

Daniela Sia, PhD, discusses a novel microenvironment-based classification system of intrahepatic cholangiocarcinoma.

Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.

Omid Hamid, MD, discusses the integration of tumor infiltrating lymphocyte–based therapy into the melanoma armamentarium.

Bhagirathbhai Dholaria, MBBS, discusses the rationale for the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Rohit Jain, MD, MPH, discusses the data from the phase 3 JAVELIN Bladder 100 trial examining avelumab as maintenance therapy following response or stable disease with first-line platinum-based chemotherapy in patients with advanced or metastatic urothelial cancer.

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

Jared Weiss, MD, discusses the efficacy results of the ongoing phase 1/2 KRYSTAL-1 trial in KRAS G12C–mutated colorectal cancer.

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Rachid Baz, MD, discusses the utility of venetoclax in patients with heavily pretreated multiple myeloma.

Maryam Lustberg, MD, MPH, discusses ongoing research in breast cancer.

Floor J. Backes, MD, discusses challenges regarding staging and treatment locations in ovarian germ cell tumors.

Andrea L. Silber, MD, discusses the importance of improving clinical trial inclusivity in breast cancer.

Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.

Kim Chi, MD, discusses the design of the phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Elisabet E. Manasanch, MD, discusses eligibility for autologous stem cell transplant in patients with multiple myeloma.

Martine Extermann, MD, PhD, discusses the significance of novel treatment options in HER2-positive breast cancer.

Nina Shah, MD, discusses the potential of vaccine-based therapies in multiple myeloma.

William P. Harris, MD, discusses remaining questions regarding treatment sequencing after atezolizumab and bevacizumab in hepatocellular carcinoma.

Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, discusses the toxicities associated with belantamab mafodotin-blmf in relapsed/refractory multiple myeloma.

Alice Indini, MD, discusses the rationale for the phase 2 PULSAR trial in classic Kaposi sarcoma.

Joel Neal, MD, PhD, discusses the FDA accelerated approval of mobocertinib in EGFR exon 20 insertion–positive non–small cell lung cancer.

Niels Reinmuth, MD, PhD, discusses the rationale for a health utility analysis of tepotinib in patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

Adam D. Cohen, MD, discusses outcomes with ciltacabtagene autoleucel, as demonstrated in the phase 2 CARTITUDE-2 study in patients with multiple myeloma.

Neeraj Agarwal, MD, discusses the design of the ongoing phase 3 AMPLITUDE trial in metastatic castration-sensitive prostate cancer.

Stacey A. Cohen, MD, discusses the shortcomings of clinical trials evaluating cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in colorectal cancer.

Alexander I. Spira, MD, PhD, FACP, discusses the impact of the PACIFIC-R trial in patients with unresectable stage III non–small cell lung cancer.

Bob T. Li, MD, PhD, MPH, discusses the results of the phase 2 DESTINY-Lung01 trial in HER2-positive metastatic non–small cell lung cancer.

Nadia Harbeck, MD, PhD, discusses the key results from the phase 2 WSG ADAPT-TP trial in patients with HER2-positive, hormone receptor–positive early-stage breast cancer.

Marina Chiara Garassino, MD, professor of Medicine, Hematology and Oncology, The University of Chicago Department of Medicine, discusses the clinical implications of the phase 2 VISION trial evaluating patients with MET exon 14 skipping mutation–positive non–small cell lung cancer.

David M. O'Malley, MD, discusses future research directions with balstilimab and zalifrelimab in patients with cervical cancer.